|Bid||8.64 x 800|
|Ask||9.73 x 1400|
|Day's Range||8.86 - 9.16|
|52 Week Range||4.53 - 9.95|
|Beta (3Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.29|
Biotech stocks got some reprieve in this week amid the release of earnings, clinical trial results presentations and positive FDA actions. Among the noteworthy developments of the week: The FDA panel ruling ...
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
On Nov. 6, detailing the company's third quarter earnings to a handful of analysts, BioCryst Pharmaceuticals' longtime CEO, Jon Stonehouse, said he sees 2019 to be a transformative year for the company.
—New loan facility increases to $50 million to further extend cash runway— —Additional $30 million available at company option following positive Phase 3 APeX-2 data—.
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present an abstract including results from the.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has appointed Steve Aselage to its board of directors. Mr. Aselage most recently served as chief executive officer of Retrophin Pharmaceuticals, a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease, which he joined in 2012. From 2005 to 2012, Mr. Aselage served as executive vice president and chief business officer of BioMarin.
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 37th Annual J.P. Morgan.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. The main goals of this trial are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in healthy subjects. BioCryst has global rights to galidesivir, a broad-spectrum antiviral drug in development to treat Marburg virus disease and Yellow Fever.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. At Shire, Ms. Heggie also built the EMEA rare disease business from $96 million to more than $750 million, and served as chief executive officer of Jerini, following Shire’s acquisition of the company, and its lead asset, Firazyr®, for the treatment of hereditary angioedema (HAE).
BioCryst (BCRX) delivered earnings and revenue surprises of -12.00% and -42.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 28 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.